Home » VTL Open Source sobre FC

VTL Open Source sobre FC

Se ha realizado en nuestro entorno de pruebas una VTL Open Source sobre FC. Su implementación está basada en los trabajos previos sobre mhVTL y SCST .

 

Partiendo del escenario descrito en los post  SCST 2 y SCST 3, donde se compiló un kernel vanilla y se le añadió el software SCST junto con los drivers de QLogic en modo target, configurado para que ofreciera a la SAN un disco virtual (VDISK). Se añade al servidor el proyecto mhVTL emulando una librería de cintas modelo Sun Storagetek L700 con un drive SDLT600 de QUANTUM, encargándose el módulo SCST de ofrecerlas a través de la HBA operando en modo Target.

El procedimiento de su implementación es:

1.- Crear entorno previo SCST descrito en el  post SCST 2.

2.- Instalar proyecto mhVTL

3.- Configurar mhVTL

4.- Configurar SCST para dar visibilidad a los elementos de mhVTL por fibra.

2.- Instalar proyecto mhVTL

La instalación es idéntica a la descrita en el artículo VTL Open Source sobre iSCSI. Brevemente,  descarga de las fuentes mhvtl en formato tar.gz desde la web del proyecto y realiza el siguiente procedimiento de instalación:

# useradd vtl
# passwd vtl
# mkdir /opt/mhvtl
# chown -Rf vtl:vtl /opt/mhvtl
# mkdir /etc/mhvtl
# chown -Rf vtl:vtl /etc/mhvtl
# cd /root/mhvtl-0.18-4
# make distclean
# cd kernel
# make
# make install
# cd ../
# make
# make install

3.- Configurar mhVTL

Edición del fichero /etc/mhvtl/device.conf  para definir  la librería y el drive:

# cat /etc/mhvtl/device.conf
VERSION: 4

# VPD page format:
# <page #> <Length> <x> <x+1>… <x+n>

# NOTE: The order of records is IMPORTANT…
# The 'Unit serial number:' should be last (except for VPD data)
# i.e.
# Order is : Vendor ID, Product ID, Product Rev and serial number finally
# Zero, one or more VPD entries.
#
# Each 'record' is sperated by one (or more) blank lines.
# Each 'record' starts at column 1

Library: 2 CHANNEL: 0 TARGET: 0 LUN: 0
Vendor identification: STK
Product identification: L700
Product revision level: 5500
Unit serial number: XYZZY

Drive: 1 CHANNEL: 0 TARGET: 1 LUN: 0
Library ID: 2 Slot: 1
Vendor identification: QUANTUM
Product identification: SDLT600
Product revision level: 5500
Unit serial number: ZF7584364
Max density: 0x46
VPD: b0 04 00 02 01 00

Definir el contenido de la librería en el fichero /etc/mhvtl/library_contents:

# cat /etc/mhvtl/library_contents
# Define how many tape drives you want in the vtl..
# The 'XYZZY_...' is the serial number assigned to
# this tape device.

Drive 1: ZF7584364

# Place holder for the robotic arm. Not really used.
Picker 1:

# Media Access Port
# (mailslots, Cartridge Access Port, <insert your favourate name here>)
# Again, define how many MAPs this vtl will contain.
MAP 1:
MAP 2:
MAP 3:
MAP 4:

# And the 'big' on, define your media and in which slot contains media.
# When the rc script is started, all media listed here will be created
# using the default media capacity.
Slot 1:    800843S3
Slot 2: 800844S3
Slot 3: 800845S3
Slot 4: 800846S3
Slot 5: 800847S3
Slot 6: 800848S3
Slot 7: 800849S3
Slot 8: 800850S3
Slot 9: 800851S3
Slot 10: 800852S3
Slot 11: 800853S3
Slot 12: 800854S3
Slot 13: 800855S3
Slot 14: 800856S3
Slot 15: 800857S3
Slot 16: 800858S3
Slot 17: 800859S3
Slot 18: 800860S3
Slot 19: 800861S3
Slot 20: 800862S3
Slot 21:
Slot 22:
Slot 23:
Slot 24:
Slot 25:
Slot 26:
Slot 27:
Slot 28:
Slot 29:
Slot 30:
Slot 31: CLN001L1
Slot 32: CLN002L1

4.- Configurar SCST para dar visibilidad a los elementos de mhVTL por fibra.

Levantar  servicio mhVTL:

/etc/init.d/mhvtl start

Comprobación:

# lsscsi
[2:0:0:0]    disk    ATA      WDC WD7500AACS-0 01.0  /dev/sda
[8:0:0:0]    mediumx STK      L700             5500  –
[8:0:1:0]    tape    QUANTUM  SDLT600          5500  –

Se observan el VDISK (procedente de prueba anterior) y la librería STK L700 junto con el drive QUANTUM SDLT600 creados por mhVTL.

Se configura para que los dispositivos sean visibles por la HBA:

# echo "add 8:0:1:0 1" > /proc/scsi_tgt/groups/Default/devices

# echo "add 8:0:0:0 2" > /proc/scsi_tgt/groups/Default/devices

Y se pone en modo target el host asociado como interfaz en sysfs:

# echo “1″ >/sys/class/scsi_host/host7/target_mode_enabled

Comprobación:

# cat /sys/class/scsi_host/host7/active_mode

Target

# cat /proc/scsi_tgt/scsi_tgt
Device (host:ch:id:lun or name)                             Device handler
2:0:0:0                                                     dev_disk
vm_disk                                                     vdisk_fileio
8:0:1:0                                                     dev_tape
8:0:0:0                                                     dev_changer

Desde el Host con W2K8 que opera en modo initiator se observan desde el administrador de dispositivos de la siguiente forma:

Se ha instalado la Utilidad OneCommand manager de Emulex con propósito de diagnóstico, la librería y el drive emulados se observan de la siguiente forma:

Para comprobar la conectividad del host con la VTL por FC  se han usado las utilidades mtx en su versión para Windows:

  • Estado de la librería:

c:\mtx>mtx.exe -f 3:0:0:2 status
Storage Changer 3:0:0:2:1 Drives, 36 Slots ( 4 Import/Export )
Data Transfer Element 0:Full (Storage Element 1 Loaded):VolumeTag = 800843S3

Storage Element 1:Empty
Storage Element 2:Full :VolumeTag=800844S3
Storage Element 3:Full :VolumeTag=800845S3
Storage Element 4:Full :VolumeTag=800846S3
Storage Element 5:Full :VolumeTag=800847S3
Storage Element 6:Full :VolumeTag=800848S3
Storage Element 7:Full :VolumeTag=800849S3
Storage Element 8:Full :VolumeTag=800850S3
Storage Element 9:Full :VolumeTag=800851S3
Storage Element 10:Full :VolumeTag=800852S3
Storage Element 11:Full :VolumeTag=800853S3
Storage Element 12:Full :VolumeTag=800854S3
Storage Element 13:Full :VolumeTag=800855S3
Storage Element 14:Full :VolumeTag=800856S3
Storage Element 15:Full :VolumeTag=800857S3
Storage Element 16:Full :VolumeTag=800858S3
Storage Element 17:Full :VolumeTag=800859S3
Storage Element 18:Full :VolumeTag=800860S3
Storage Element 19:Full :VolumeTag=800861S3
Storage Element 20:Full :VolumeTag=800862S3
Storage Element 21:Empty
Storage Element 22:Empty
Storage Element 23:Empty
Storage Element 24:Empty
Storage Element 25:Empty
Storage Element 26:Empty
Storage Element 27:Empty
Storage Element 28:Empty
Storage Element 29:Empty
Storage Element 30:Empty
Storage Element 31:Full :VolumeTag=CLN001L1
Storage Element 32:Full :VolumeTag=CLN002L1
Storage Element 33 IMPORT/EXPORT:Empty
Storage Element 34 IMPORT/EXPORT:Empty
Storage Element 35 IMPORT/EXPORT:Empty
Storage Element 36 IMPORT/EXPORT:Empty

  • Información de la librería:

c:\mtx>tapeinfo.exe -f 3:0:0:2
Product Type: Medium Changer
Vendor ID: 'STK     '
Product ID: 'L700            '
Revision: '5500'
Attached Changer API: No
SerialNumber: 'XYZZY     '
Ready: yes

  • Información del drive:

c:\mtx>tapeinfo.exe -f Tape0
Product Type: Tape Drive
Vendor ID: 'QUANTUM '
Product ID: 'SDLT600         '
Revision: '5500'
Attached Changer API: No
SerialNumber: 'ZF7584364 '
MinBlock: 4
MaxBlock: 1048576
Ready: yes
BufferedMode: yes
Medium Type: Not Loaded
Density Code: 0x49
BlockSize: 0
DataCompEnabled: yes
DataCompCapable: yes
DataDeCompEnabled: yes
CompType: 0x10
DeCompType: 0x10
BOP: yes
Block Position: 0
Partition 0 Remaining Kbytes: 499
Partition 0 Size in Kbytes: 500
ActivePartition: 0
EarlyWarningSize: 0
NumPartitions: 0
MaxPartitions: 0

  • Carga de cinta de Slot 1 a drive 0:

c:\mtx>mtx.exe -f 3:0:0:2 load 1 0
Loading media from Storage Element 1 into drive 0…done

  • Descarga de drive 0 a slot 1:

c:\mtx>mtx.exe -f 3:0:0:2 unload 1 0
Unloading drive 0 into Storage Element 1…done

Como se puede observar la librería virtual opera correctamente a las peticiones descritas a través de FC.

Fuentes:

Proyecto mhvtl

Proyecto SCST

Foros de nimsa

Blog nsrd.info

One Response to “VTL Open Source sobre FC”

  1. My brother recommended I would possibly like this blog.
    He was entirely right. This put up truly made my day.
    You can not consider simply how a lot time I had spent for this
    information! Thanks!

  2. bitly.com dice:

    A fascinating discussion is worth comment. I think that you need to write more on this issue, it may not be a taboo
    matter but generally people don’t speak about such issues.
    To the next! Many thanks!!

  3. bit.ly dice:

    What’s up it’s me, I am also visiting this web page
    on a regular basis, this web page is in fact good and the viewers are actually sharing good thoughts.

  4. JustinJulky dice:

    A errant II mull to led via researchers from The University of Texas MD Anderson Cancer Center evolve that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% dispassionate talent amount in patients with advanced mortal peritoneal mesothelioma, a rare cancer in the lining of the abdomen. Responses occurred in patients regardless of PD-L1 enunciation motionless and tumor varying burden.

    Side results indicated that the coalition was crypt and prominent in patients with grumble pomp or illiberality to aforementioned chemotherapy treatment. The cram, led all routine of Kanwal Raghav, M.D., associate professor of Gastrointestinal Medical Oncology, and Daniel Halperin, M.D., subordinate professor of Gastrointestinal Medical Oncology, was published today in Cancer Discovery.

    Noxious peritoneal mesothelioma (MPeM) is known as a rare but insolent ailment with historically trifling survival and non-productive treatment options. Because symptoms most over and beyond again elapse out of the closet unheard, peritoneal cancer is in the outstanding diagnosed at a theme stage. If hitherto larboard untreated, organism expectancy is oft less than a year.

    Bromide of the prime trials because MPeM patients

    Researchers at prerogative gone from that 300-500 Americans are diagnosed with MPeM each year. MPeM in the main follows the an eye to all that treatment as pleural mesothelioma, a cancer of the lung lining, although there are pithy differences between the diseases. MPeM is by a long chalk everywhere rarer, understudied, has a weaker intimacy with asbestos airing, affects women more oftentimes, occurs at a younger epoch and is diagnosed more during again at an advanced stage.

    Treatment strategies are varying, but most of the conditions encompass optimal cytoreductive surgery, hypothermic intraoperative peritoneal perfusion with chemotherapy (HIPEC) or betimes postoperative intraperitoneal chemotherapy (EPIC). Patients with MPeM foremost are treated following the recommendations as high as something severe pleural mesothelioma and most studies on chemotherapy drugs support been done pursue of pleural mesothelioma, repeatedly excluding MPeM patients.

    The Jingoistic Broad Cancer Network (NCCN) recommends first-line platinum chemotherapy allowing as a servicing to on both mesotheliomas, but after powerlessness gaining cross there is no established treatment plot or any Comestibles and Panacea Administration-approved treatments use of advanced MPeM.

    This single-center ruminate approximately is a multicohort basket be disturbed extras of fortitude of atezolizumab and bevacizumab in a identify of advanced cancers. Atezolizumab is a classification of immunotherapy narcotize called an insusceptible checkpoint inhibitor that targets PD-L1, while bevacizumab is a targeted psychotherapy that slows the augmentation of brand-new blood vessels through inhibiting vascular endothelial spread representative (VEGF). This publication reports figures after the 20 patients in the MPeM cohort. The median seniority was 63 years, 60% of participants were women and 75% self-reported that they had not been exposed to asbestos. Try on participants were 80% deathly ivory, 10% Hispanic, 5% Ebony and 5% other.

    Late to enrolling in this clinical discompose, patients who received gonfanon of misappropriate into account chemotherapy progressed to next treatment at 8.3 months compared to 17.6 months with atezolizumab and bevacizumab on the study. The median comeback duration was 12.8 months.

    Progression-free and overall survival at inseparable year were 61% and 85%, respectively. The treatment was well-tolerated, with the most non-private events being hypertension and anemia.

    “Patients treated on this regimen surpassed outcomes expected with expected therapies,” Raghav said. “This figures shows that this is a brainy treatment election and reiterates the value of clinical trials on the side of rare cancers to magnetism loose grasping survival.”

    Biomarker run-down

    Integration of biopsies winning and during treatment established the practicability and the value of a translationally motivated method in rare cancers. Using the biopsies, the researchers demonstrated that the clinical bustle seen with this treatment associated with did not correlate with clinically established biomarkers of rebuttal to vaccinated checkpoint meddling in other tumors.

    The biomarker examination identified that epithelial-mesenchymal change-over (EMT) gene airing, which is a cancer illustriousness associated with a more quarrelsome biology, correlated with litigious sickness, treatment partisans and poorer respond rates.

    To limit a tumor mise en level predictive of return to this opiate treatment, researchers examined pre-treatment unsusceptible come to a standstill subsets using 15 agree unswerving samples. They create that VEGF impediment improves the effectiveness of inoculated checkpoint inhibitors not later than adapting the immunosuppressive tumor environment.

    “I am quite encouraged away the responses to this treatment, and I am ruddy that with additional scrutinization this pass on purvey a more wisely treatment unexpected against these patients,” Raghav said. “I am on cloud nine looking with a view the patients who are tickled pink to participate in clinical trials and benefit recent our skill of rare cancers.”

    Additional trials with larger numbers of patients are needed to validate these bone up on results, stop if this panacea parasynthesis could be premised as frontline treatment or remodel surgical outcomes after these patients.

    https://telegra.ph/mesothelioma-symptoms-latency-06-26-2
    https://tgraph.io/mESOTHELIOMA-gENETICS-06-26-4
    https://tgraph.io/mESOTHELIOMA-wORKUP-06-26-5
    https://te.legra.ph/epithelioid-mesothelioma-survival-rate-06-26-3
    https://tgraph.io/first-symptoms-of-mesothelioma-06-26-3
    https://telegra.ph/hOW-bAD-iS-mESOTHELIOMA-06-26-3
    https://te.legra.ph/CAN-CATS-GET-MESOTHELIOMA-06-26-2
    https://te.legra.ph/Mesothelioma-Symptoms-And-Causes-06-26-3
    https://tgraph.io/how-to-diagnose-peritoneal-mesothelioma-06-26-2
    https://issuu.com/jasonnwto/docs/fast_commercial_hard_money_loans
    https://te.legra.ph/bIPHaSIC-mESothelIoMA-ImmUNothErApy-06-26-3
    https://telegra.ph/mesothelioma-and-asbestos-exposure-06-26-3
    https://tgraph.io/how-long-does-it-take-to-get-mesothelioma-06-26-2
    https://te.legra.ph/mesothelioma-cancer-what-is-it-06-26-4
    https://tgraph.io/aVERAGE-pAYOUT-fOR-mESOTHELIOMA-sETTLEMENT-06-26-4
    https://te.legra.ph/aVErAge-MESOthELIoMA-SETTLeMeNT-amouNtS-2022-06-26
    https://telegra.ph/how-do-you-test-for-mesothelioma-06-26-3
    https://tgraph.io/benign-multicystic-peritoneal-mesothelioma-06-26-2
    https://te.legra.ph/lAB-tEST-fOR-mESOTHELIOMA-06-26-3
    https://issuu.com/savoeunfqjqc/docs/fast_money_loan_long_beach_phone_number
    https://te.legra.ph/peritoneal-mesothelioma-pathology-06-26-2
    https://telegra.ph/PleuRAL-meSOThELioMA-sTaGes-06-26-4
    https://te.legra.ph/Mesothelioma-Cure-Found-06-26-3
    https://telegra.ph/Mesothelioma-Life-Expectancy-Stage-1-06-26-3
    https://telegra.ph/how-long-does-mesothelioma-last-06-26
    https://te.legra.ph/can-you-get-mesothelioma-from-06-26-3
    https://tgraph.io/best-mesothelioma-lawyers-in-texas-06-26-2
    https://telegra.ph/MESOTHELIOMA-LUNG-CANCER-SURVIVAL-RATE-06-26-2
    https://te.legra.ph/IS-MESOTHELIOMA-COMMUNICABLE-06-26-2
    https://issuu.com/savoeunfqjqc/docs/fast_money_loans_near_me
    https://telegra.ph/AsBEstOs-cANCER-mESOThElIOMA-symPtoMs-06-26-2
    https://tgraph.io/how-to-know-if-you-have-mesothelioma-06-26-2
    https://telegra.ph/HOw-dOeS-one-Get-MesOtheLiOMa-06-26-2
    https://tgraph.io/malignant-pleural-mesothelioma-treatment-06-26-3
    https://te.legra.ph/early-symptoms-mesothelioma-06-26-4
    https://te.legra.ph/Spelling-Mesothelioma-06-26
    https://te.legra.ph/best-mesothelioma-centers-06-26-2
    https://tgraph.io/best-mesothelioma-law-firms-06-26-2
    https://telegra.ph/MESOTHELIOMA-AND-ASBESTOS-SYMPTOMS-06-26-2
    https://issuu.com/adamhyho/docs/fast_money_loans_ca
    https://tgraph.io/malignant-mesothelioma-symptoms-06-26-4
    https://telegra.ph/diagnostic-test-for-mesothelioma-06-26-4
    https://te.legra.ph/Prevention-Of-Mesothelioma-06-26-3
    https://tgraph.io/epithelioid-malignant-peritoneal-mesothelioma-06-26-2
    https://telegra.ph/mESoTHelIOma-caNcER-aSbEsToS-06-26-4
    https://telegra.ph/icd-10-code-for-sarcomatoid-mesothelioma-06-26
    https://telegra.ph/Why-Is-Mesothelioma-So-Deadly-06-26-3
    https://tgraph.io/how-do-you-get-mesothelioma-cancer-06-26-2
    https://telegra.ph/sARcOMAToID-mESOthELIomA-DiagNOsIs-06-26-6
    https://issuu.com/adamhyho/docs/fast_money_loans_personal_loans
    https://telegra.ph/mesothelioma-lung-cancer-survival-rate-06-26-3
    https://tgraph.io/mesothelioma-symptoms-and-signs-06-26-2
    https://telegra.ph/how-does-one-get-mesothelioma-06-26-2
    https://telegra.ph/mesothelioma-cancer-survival-rate-06-26
    https://telegra.ph/is-mesothelioma-malignant-06-26-3
    https://tgraph.io/malignant-mesothelioma-pathology-outlines-06-26
    https://telegra.ph/mesothelioma-stage-4-survival-rate-06-26-3
    https://telegra.ph/where-does-mesothelioma-spread-06-26-5
    https://telegra.ph/best-mesothelioma-treatment-centers-06-26-3
    https://issuu.com/adamhyho/docs/fast_money_loans_long_beach_ca
    https://te.legra.ph/Average-Payout-For-Mesothelioma-Settlement-06-26-3
    https://tgraph.io/How-To-Say-Mesothelioma-06-26-3
    https://telegra.ph/signs-symptoms-of-mesothelioma-06-26-4
    https://tgraph.io/desmoplastic-mesothelioma-pathology-06-26-3
    https://te.legra.ph/how-does-someone-get-mesothelioma-06-26
    https://tgraph.io/how-is-mesothelioma-staged-06-26-2
    https://telegra.ph/how-to-test-for-mesothelioma-06-26-5
    https://te.legra.ph/mesothelioma-tenderness-pain-chest-06-26-5
    https://tgraph.io/what-causes-malignant-mesothelioma-06-26-4
    https://tgraph.io/iS-mESOTHELIOMA-sMALL-cELL-lUNG-cANCER-06-26-2
    https://telegra.ph/Mesothelioma-How-Long-To-Live-06-26-3
    https://issuu.com/jasonnwto/docs/fast_hard_money_business_loans
    https://te.legra.ph/mesothelioma-prevention-06-26-4
    https://te.legra.ph/is-mesothelioma-caused-by-smoking-06-26-3
    https://te.legra.ph/what-is-the-symptoms-of-mesothelioma-06-26-3
    https://te.legra.ph/peritoneal-mesothelioma-pathology-06-26-3
    https://telegra.ph/End-Stage-Peritoneal-Mesothelioma-Cancer-06-26
    https://tgraph.io/how-common-is-mesothelioma-06-26-3
    https://telegra.ph/desmoplastic-sarcomatoid-mesothelioma-06-26-4
    https://telegra.ph/hOW-cAN-yOU-pREVENT-mESOTHELIOMA-06-26-3
    https://issuu.com/savoeunfqjqc/docs/easy_money_loans_for_bad_credit
    https://telegra.ph/lung-cancer-mesothelioma-symptoms-06-26
    https://te.legra.ph/HOW-TO-DIAGNOSE-PERITONEAL-MESOTHELIOMA-06-26-2
    https://te.legra.ph/how-Do-yOU-detEct-MesOtheLIOmA-06-26-5
    https://telegra.ph/lung-mesothelioma-pathology-outline-06-26-5
    https://te.legra.ph/color-for-mesothelioma-cancer-ribbons-06-26-3
    https://te.legra.ph/sARComAtoId-MESoTheLiOMA-PaTholOgy-OuTLiNES-06-26-5
    https://te.legra.ph/mesothelioma-pleural-effusion-stage-06-26-2
    https://issuu.com/jasonnwto/docs/fast_money_loans_no_credit_check
    https://telegra.ph/bipHASIc-meSOTHeLioMA-pAtHOlOgy-06-26-2
    https://tgraph.io/HOW-MUCH-IS-A-MESOTHELIOMA-CASE-WORTH-06-26-2
    https://telegra.ph/mesothelioma-and-asbestos-exposure-06-26-3
    https://telegra.ph/mesothelioma-workers-comp-06-26-3
    https://te.legra.ph/Malignant-Mesothelioma-Symptoms-06-26-3
    https://te.legra.ph/benign-mesothelioma-abdomen-06-26-2
    https://telegra.ph/mesothelioma-peritoneal-symptoms-06-26-3
    https://te.legra.ph/how-is-mesothelioma-treated-06-26-2
    https://tgraph.io/signs-symptoms-of-mesothelioma-06-26-3
    https://issuu.com/adamhyho/docs/get_money_fast_loans
    https://te.legra.ph/is-mesothelioma-malignant-06-26-5

Responder a bitly.com Cancelar respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *